Drug Profile

ARCT 2138

Alternative Names: ARCT-2138

Latest Information Update: 01 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arcturus Therapeutics
Class Influenza virus vaccines; RNA vaccines
Mechanism of Action Dendritic cell modulators; Protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Influenza virus infections

Most Recent Events

11 Aug 2025 Immunogenicity and adverse events data from a phase I trial in Influenza virus infections (Prevention) released by Arcturus Therapeutics
07 Jan 2025 Arcturus Therapeutics completes a phase I trial in Influenza virus infections (Prevention) in Australia (IM) (NCT06125691)
22 Jan 2024 Phase-I clinical trials in Influenza virus infections (Prevention) in Australia (IM) , (NCT06125691)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com